MOTS-c vs Semaglutide
A side-by-side research comparison of MOTS-c and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MOTS-c | Semaglutide |
|---|---|---|
| Full name | Mitochondrial Open Reading Frame of the 12S rRNA-c | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | Activates AMPK pathway, enhances mitochondrial metabolism, improves insulin sensitivity by increasing GLUT4 translocation, and promotes fatty acid oxidation. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 2,175 Da | 4,114 Da |
| Half-life | 4-8 hours | 7 days (168 hours) |
| Bioavailability | Moderate (SubQ) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 5-10 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | 3-5x per week | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
MOTS-c reported benefits
- Exercise mimetic effects
- Improved insulin sensitivity
- Enhanced fat oxidation
- Metabolic homeostasis
- Anti-aging metabolic benefits
- AMPK activation
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.